Needham & Company Starts Celator Pharmaceuticals (CPXX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
Celator Pharmaceuticals (CPXX) Sees Second Day of Big Gains
April 13, 2016 12:40 PM EDTCelator Pharmaceuticals (NASDAQ: CPXX) is adding to Tuesday's big gains following positive analyst coverage yesterday.
Needham & Company... MoreUPDATE: Roth Sees Celator Pharma's (CPXX) Vyxeos Easily Supplementing Standard of Care 7+3 Therapy; Affirms at 'Buy'
April 12, 2016 7:52 AM EDT(Updated - April 12, 2016 8:04 AM EDT)
Roth Capital is offering commentary on Celator Pharmaceuticals (Nasdaq: CPXX) following recent positive Phase 3 data from the company. The firm reiterates its Buy rating and $22 price target on Celator.
Analyst Joseph Pantginis... More
